Revolutionizing Mental Healthcare: Cybin Inc.'s Innovative Drug Development
Update: 2025-11-05
Description
Cybin Inc., a Phase 3 clinical stage neuropsychiatry company, is set to have their Chief Business Officer speak at the Guggenheim 2nd Annual Healthcare Innovation Conference. The company is dedicated to transforming mental healthcare through the development of novel drugs like CYB003 and CYB004 for major depressive disorder and generalized anxiety disorder, respectively, with the goal of providing effective and lasting treatment options.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
